keyword
MENU ▼
Read by QxMD icon Read
search

Lysis syndrome tumor

keyword
https://www.readbyqxmd.com/read/29749403/obinutuzumab-plus-bendamustine-in-previously-untreated-patients-with-cll-a-subgroup-analysis-of-the-green-study
#1
Stephan Stilgenbauer, Veronique Leblond, Robin Foà, Sebastian Böttcher, Osman Ilhan, Wolfgang Knauf, Eva Mikuskova, Christoph Renner, Eugen Tausch, Dariusz Woszczyk, Ekaterina Gresko, Linda Lundberg, Tom Moore, Thea Morris, Susan Robson, Francesc Bosch
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab-bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2-6; and bendamustine 70/90 mg/m2 D1 and D2 of C1-6. The primary endpoint was safety/tolerability...
April 27, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29725528/-blastoid-variant-of-burkitt-lymphoma-with-additional-partial-1q-tetrasomy
#2
Ahsan Siddiqi, Sheshadri Madhusudhana, Alexey Glazyrin
Burkitt lymphoma is cytogenetically characterized by t(8;14)(q24;q32) translocation, sometimes accompanied by additional cytogenetic abnormalities. These abnormalities usually result in more aggressive clinical presentation and morphology of the disease. The current report presens a case of Burkitt lymphoma with t(8;14)(q24;q32) accompanied by partial tetrasomy of chromosome 1(47,XY,+1,i(1)(q10),t(8;14)(q24;q32)[2]/46,XY[18]). The patient was a 59-year-old male who presented with abdominal pain, leukocytosis and tumor lysis syndrome...
May 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29691710/colorectal-cancer-associated-spontaneous-tumor-lysis-syndrome-a-case-report-and-review-of-the-current-literature
#3
Matthew R Kearney, Emerson Y Chen, Peter Stenzel, Christopher L Corless, Thomas G Deloughery, Mark Zivney, Charles D Lopez
No abstract text is available yet for this article.
April 25, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29686562/spontaneous-tumor-lysis-syndrome-in-small-cell-lung-cancer
#4
Ryan K Dean, Rogin Subedi, Mijung Lee
Tumor lysis syndrome is a set of metabolic disturbances that can be seen during the destruction of tumor cells and is an oncologic and metabolic emergency. The syndrome is rare in those with solid tumors, and even more rare in those with solid tumors who have not yet received chemotherapy. We present a case of tumor lysis syndrome in a patient with small cell lung cancer.
January 2018: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/29684339/sorafenib-induced-tumor-lysis-syndrome-in-a-patient-with-metastatic-hepatocellular-carcinoma
#5
Sardar Zakariya Imam, Mohammad Faizan Zahid, Muhammad Asad Maqbool
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1-2 weeks while being treated...
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29608741/critically-elevated-potassium-in-a-55-year-old-female-with-chronic-lymphocytic-leukemia
#6
Jing Cao, Amy B Karger
Hyperkalemia in specimens from patients with chronic lymphocytic leukemia (CLL) may be due to tumor lysis syndrome (TLS) or specimen processing. This report describes a 55-year-old Caucasian woman with CLL who presented to an outside hospital with hyperkalemia and was transferred to a second hospital. Initial evaluation on the core laboratory chemistry analyzer (the VITROS 5600) and the ABL90 FLEX blood gas analyzer showed markedly elevated levels of potassium (K+). TLS was subsequently diagnosed, and dialysis was initiated...
March 28, 2018: Laboratory Medicine
https://www.readbyqxmd.com/read/29590547/ibrutinib-plus-venetoclax-for-the-treatment-of-mantle-cell-lymphoma
#7
COMPARATIVE STUDY
Constantine S Tam, Mary Ann Anderson, Christiane Pott, Rishu Agarwal, Sasanka Handunnetti, Rodney J Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David Westerman, Stephen Lade, Martin Dreyling, Sarah-Jane Dawson, Mark A Dawson, John F Seymour, Andrew W Roberts
BACKGROUND: Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination. METHODS: We conducted a single-group, phase 2 study of daily oral ibrutinib and venetoclax in patients, as compared with historical controls. Patients commenced ibrutinib monotherapy at a dose of 560 mg per day...
March 29, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29562156/venetoclax-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia
#8
RANDOMIZED CONTROLLED TRIAL
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P Kater
BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group)...
March 22, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29556297/abnormal-populations-and-functions-of-natural-killer-cells-in-patients-with-myelodysplastic-syndromes
#9
Wei Zhang, Xinyan Xie, Huijing Mi, Jinwan Sun, Shaoxue Ding, Lijuan Li, Hui Liu, Huaquan Wang, Rong Fu, Zonghong Shao
Myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis that lead to leukemia. Disorders of the immune system serve important functions in the pathophysiology and progression of this disease. Different levels or mechanisms of natural killer (NK) cells in patients with MDS have been measured in previous studies, making it challenging to understand the pathogenesis of NK cytotoxicity. The present study investigated the frequency of NK cell-mediated antibody-dependent cellular cytotoxicity and explored the function of NK cells by their activating receptors, inhibition signals, degranulation and cytotoxicity factors...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29531724/fatal-cardiac-arrhythmia-caused-by-tumor-lysis-in-a-patient-with-diffuse-large-b-cell-lymphoma-upon-start-of-r-chop
#10
Nina Sørensen, Paw Jensen, Erik Clasen-Linde, Jacob Moesgaard Larsen, Tarec El-Galaly
Tumor lysis syndrome is rare in diffuse large cell lymphoma, but it is important to recognize the risk in patients with massive tumor burden and reduced kidney function. Very intense vigilance can be necessary despite adequate prophylactic measures and certain drugs may exacerbate electrolyte derangements.
March 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29508029/-oncological-emergencies-in-chemotherapy-febrile-neutropenia-tumor-lysis-syndrome-and-extravasation
#11
REVIEW
G von Amsberg
BACKGROUND: Uro-oncological emergencies can be caused by the tumor, treatment complications, or non-oncological diseases. This review focuses on chemotherapy-associated emergencies, especially febrile neutropenia (FN), tumor lysis syndrome (TLS), and extravasations. AIM: The goal is to provide an overview on the most relevant chemotherapy-associated emergencies and treatment methods. MATERIALS AND METHODS: The ESMO (European Society of Medical Oncology), EORTC (European Organization for Research and Treatment of Cancer), and S3 guidelines were used for the preparation of this review and a PubMed search was performed for "febrile neutropenia", "extravasation", and "tumor lysis syndrome"...
May 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29496260/hyperuricemia-acute-and-chronic-kidney-disease-hypertension-and-cardiovascular-disease-report-of-a-scientific-workshop-organized-by-the-national-kidney-foundation
#12
Richard J Johnson, George L Bakris, Claudio Borghi, Michel B Chonchol, David Feldman, Miguel A Lanaspa, Tony R Merriman, Orson W Moe, David B Mount, Laura Gabriella Sanchez Lozada, Eli Stahl, Daniel E Weiner, Glenn M Chertow
Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. A scientific workshop organized by the National Kidney Foundation was held in September 2016 to review current evidence. Cell culture studies and animal models suggest that elevated serum urate concentrations can contribute to kidney disease, hypertension, and metabolic syndrome. Epidemiologic evidence also supports elevated serum urate concentrations as a risk factor for the development of kidney disease, hypertension, and diabetes, but differences in methodologies and inpacts on serum urate concentrations by even subtle changes in kidney function render conclusions uncertain...
February 26, 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29484126/retargeting-of-unicar-t-cells-with-an-in-vivo-synthesized-target-module-directed-against-cd19-positive-tumor-cells
#13
Dominik Bachmann, Roberta Aliperta, Ralf Bergmann, Anja Feldmann, Stefanie Koristka, Claudia Arndt, Simon Loff, Petra Welzel, Susann Albert, Alexandra Kegler, Armin Ehninger, Marc Cartellieri, Gerhard Ehninger, Martin Bornhäuser, Malte von Bonin, Carsten Werner, Jens Pietzsch, Jörg Steinbach, Michael Bachmann
Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case of cross-reactivities, CAR T cells may also attack healthy tissues. To overcome these limitations, we previously established a switchable CAR platform technology termed UniCAR. UniCARs are not directed against typical tumor-associated antigens (TAAs) but instead against a unique peptide epitope: Fusion of this peptide epitope to a recombinant antibody domain results in a target module (TM)...
January 26, 2018: Oncotarget
https://www.readbyqxmd.com/read/29464464/pazopanib-related-tumor-lysis-syndrome-in-metastatic-clear-cell-renal-cell-carcinoma-a-case-report
#14
Michael W van Kalleveen, Maudy Walraven, Mathijs P Hendriks
Introduction Tumor lysis syndrome (TLS) is a life-threatening emergency caused by rapid cell death as a result of anti-tumor therapy. In the era of targeted therapy it has increasingly been observed in solid malignancies such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Case We describe the case of a 58-year old man with the medical history of a memorial sloan kettering cancer centre (MSKCC) poor prognosis metastasized clear cell renal cell carcinoma (mRCC) who developed TLS within six days after initiating therapy with the tyrosine kinase inhibitor (TKI) pazopanib...
February 20, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29434608/a-case-of-type-2-hypersensitivity-to-rasburicase-diagnosed-with-a-natural-killer-cell-activation-assay
#15
Sébastien Viel, Rémi Pescarmona, Alexandre Belot, Audrey Nosbaum, Christine Lombard, Thierry Walzer, Frédéric Bérard
Drug hypersensitivity reactions can lead to different clinical pictures depending on the underlying immunological mechanism. Diagnosis tests are already available to assess the most frequent drugs hypersensitivity reactions, which are mediated by specific IgE or T cells. However, it remains challenging to diagnose type 2 hypersensitivity reactions (T2HR), which can lead to severe cytopenia and liver failure. Here, we describe a case of T2HR to rasburicase, an uricolytic agent used to prevent tumor lysis syndrome...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29427353/rapid-reduction-of-extremely-high-kappa-free-light-chains-in-a-patient-with-myeloma-cast-nephropathy
#16
Christine L H Snozek, Theresa N Kinard, Jill Adamski
This report describes a patient with light chain myeloma and acute renal injury. Serum kappa free light chain (FLC) was extremely elevated, >33,000 mg/dL. Treatment with therapeutic plasma exchange (TPE) started day 2 for biopsy-confirmed cast nephropathy. Bortezomib-containing chemotherapy was initiated on day 5, and hemodialysis for tumor lysis syndrome on day 7. TPE alone decreased kappa FLC >70% by day 5, indicating direct FLC removal was successful in this patient. A total of 25 TPE procedures were performed in a 31-day hospitalization...
February 10, 2018: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/29393097/uric-acid-the-lower-the-better
#17
Gianni Bellomo, Antonio Selvi
BACKGROUND: Uric acid (UA) is still considered a risk factor, or even a causative agent, for chronic kidney disease (CKD); however, a few, important, clinical questions remain unanswered; in particular: when and whether urate-lowering therapy should be commenced in subjects with asymptomatic hyperuricemia and/or monosodium urate crystals deposition? What is the most appropriate UA target to be achieved and how long does it need to be maintained? How does treatment need be adjusted in patients with chronic kidney disease? SUMMARY: The observational and intervention studies available do not fully answer such questions, and a treatment to target trial is required...
2018: Contributions to Nephrology
https://www.readbyqxmd.com/read/29373361/urgent-chemotherapy-in-sepsis-like-shock-related-to-hematologic-malignancies
#18
Marlène Cherruault, Marielle Le Goff, Jérôme Tamburini, Frédéric Pène
OBJECTIVES: Hematologic malignancies may result in multiple organ involvement including pulmonary and renal dysfunctions, and the less common acute circulatory failure. We herein addressed the outcome of patients with sepsis-like shock related to aggressive hematologic malignancies. DESIGN: A 10-year (2007-2016) monocenter retrospective study. SETTINGS: A medical ICU in a tertiary care center. PATIENTS: Patients with circulatory shock requiring vasopressors and who subsequently received chemotherapy...
May 2018: Critical Care Medicine
https://www.readbyqxmd.com/read/29368008/-cancer-patients-in-operative-intensive-care-medicine
#19
REVIEW
T Annecke, A Hohn, B Böll, M Kochanek
Cancer is one of the leading causes of death worldwide. New targeted and individualized therapies and drugs provide a survival benefit for an increasing number of patients, but can also cause severe side effects. An increasing number of oncology patients are admitted to intensive care units (ICU) because of cancer-related complications or treatment-associated side effects. Postoperative care, respiratory distress and sepsis are the leading causes for admission. Tumor mass syndromes and tumor lysis may require urgent treatment...
January 24, 2018: Der Anaesthesist
https://www.readbyqxmd.com/read/29363928/managing-patients-with-oncologic-complications-in-the-emergency-department-digest
#20
David Wacker, Michael T McCurdy, Jeffrey Nusbaum, Nachi Gupta
As the prevalence of cancer continues to increase in the general population and improvements in cancer treatment prolong survival, the incidence of patients presenting to the emergency department with oncologic complications will, similarly, continue to rise. This issue reviews 3 of the more common presentations of oncology patients to the emergency department: metastatic spinal cord compression, tumor lysis syndrome, and febrile neutropenia. Signs and symptoms of these conditions can be varied and nonspecific, and may be related to the malignancy itself or to an adverse effect of the cancer treatment...
January 22, 2018: Emergency Medicine Practice
keyword
keyword
55484
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"